Therapeutics News and Research

RSS

ARYx secures bridge financing, reports decrease in net loss to $3.6M for second-quarter 2010

ARYx Therapeutics, Inc. today announced that it has secured bridge financing to allow ARYx time and resources to potentially complete a transaction that could create significant value for stockholders. ARYx also released its financial results for the second quarter of 2010.

16 Aug 2010

EntreMed second quarter 2010 net loss increases to $0.62 per share

EntreMed, Inc.,a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and six-month periods ending June 30, 2010.

16 Aug 2010

Nile Therapeutics second quarter 2010 net loss decreases to $1.5 million

Nile Therapeutics, Inc.,a company focused on the development of novel therapeutics for heart failure patients, today announced its second quarter financial results for 2010.

16 Aug 2010

CTI announces EMEA's validation of expanded PIP for pixantrone

Cell Therapeutics, Inc. announced today that it has received notice that the European Medicines Agency has validated the expanded Pediatric Investigation Plan that CTI filed in July for pixantrone for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL).

16 Aug 2010

Nymox second-quarter net loss increases to $1.75 million

Nymox Pharmaceutical Corporation announced today its financial results for the second quarter of 2010. Nymox reported a net loss of $1,745,798, or $0.05 per share for the quarter and $3,015,348, or $0.10 per share for the six months ending June 30, 2010, compared to $1,220,152, or $0.04 per share for the quarter and $2,224,411, or $0.07 per share for the six months ending June 30, 2009. Net losses include stock compensation charges for the quarter of $245,245 in 2010 and $248,886 in 2009 and for the six months ending June 30 of $440,465 in 2010 and $558,536 in 2009.

16 Aug 2010

Scientists discover new signaling pathway to reduce tumour growth in glioblastoma multiforme

Malignant gliomas are the most common subtype of primary brain tumor - and one of the deadliest. Even as doctors make steady progress treating other types of solid tumor cancers, from breast to prostate, the most aggressive form of malignant glioma, called a glioblastoma multiforme or GBM, has steadfastly defied advances in neurosurgery, radiation therapy and various conventional or novel drugs. But an international team of scientists, headed by researchers at the Ludwig Institute for Cancer Research (LICR) at the University of California, San Diego School of Medicine, reports in the August 15 issue of Genes & Development that they have discovered a new signaling pathway between GBM cells - one that, if ultimately blocked or disrupted, could significantly slow or reduce tumor growth and malignancy.

16 Aug 2010

Common genetic variation in HLA region associated with late-onset sporadic Parkinson's disease: Research

A team of researchers has discovered new evidence that Parkinson's disease may have an infectious or autoimmune origin. "Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease" appears online in Nature Genetics.

16 Aug 2010

CRF announces additional featured trials to be presented at Transcatheter Cardiovascular Therapeutics 2010

The Cardiovascular Research Foundation has announced that in addition to the previously announced late breaking clinical trials and first reports, a series of additional featured trials will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium. These trials will focus on a wide range of significant topics in interventional cardiovascular medicine. TCT 2010 will take place September 21 - 25 in Washington, DC.

13 Aug 2010

Trubion Pharmaceuticals signs definitive merger agreement with Emergent BioSolutions

Trubion Pharmaceuticals, Inc. today announced the signing of a definitive merger agreement with Emergent BioSolutions Inc., in which Emergent has agreed to acquire Trubion. Under the terms of the agreement, each share of Trubion common stock will be converted into the right to receive an upfront payment of $1.365 per share in cash and 0.1641 shares of Emergent BioSolutions common stock.

13 Aug 2010

Pro-Pharmaceuticals second-quarter net loss applicable to common stock decreases to $2.5 million

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the second quarter and the first six months ended June 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.

13 Aug 2010

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

Mercator Therapeutics, the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs, today announced the signing of a license agreement with The University of Texas MD Anderson Cancer Center and the closing of a $2.0 million seed round.

13 Aug 2010

Epitomics spins-out Apexigen to develop and commercialize humanized rabbit monoclonal antibodies

Epitomics, Inc. today announced that it has spun-out to its shareholders a new biotechnology company called Apexigen, Inc., which will focus on the development and commercialization of humanized monoclonal antibodies for treatment of cancer and immuno-disorders.

13 Aug 2010

Guided Therapeutics second-quarter service revenue increases to $0.8 million

Guided Therapeutics, Inc. today announced its operating results for the second quarter and first six months of 2010.

13 Aug 2010

Akela reports $0.1M net income for second-quarter 2010 vs. $1.1M net loss for same period in 2009

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today announced its financial results for the three and six months ended June 30, 2010.

13 Aug 2010

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

13 Aug 2010

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).

13 Aug 2010

Emergent BioSolutions enters agreement to acquire Trubion Pharmaceuticals

Emergent BioSolutions Inc. announced today it has entered into a definitive agreement to acquire Trubion Pharmaceuticals, Inc. for upfront consideration of $96.8 million of value and up to $38.7 million of success-based milestones, resulting in a total consideration of up to $135.5 million. The acquisition will diversify Emergent's product development pipeline with the addition of Trubion's two clinical-stage product candidates focused on the targeted disease areas of oncology and autoimmunity.

13 Aug 2010

Halozyme Therapeutics granted U.S. patent for recombinant human hyaluronidase enzyme platform

Halozyme Therapeutics, Inc. today announced the issuance of U.S. Patent No. 7,767,429 claiming its proprietary recombinant human hyaluronidase enzyme platform (rHuPH20). Claims to the human PH20 glycoprotein, PEGylated variants, the glycoprotein produced by recombinant methods, and pharmaceutical compositions with other agents, including antibodies, insulins, cytokines, anti-infectives and additional therapeutic classes were awarded in the '429 patent. Additional claims are in prosecution.

12 Aug 2010

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Amorfix Life Sciences, a product development company focused on misfolded protein diseases, today announced its operational and financial results for the three months ended June 30, 2010.

12 Aug 2010

FDA grants BioMimetic Therapeutics orphan drug designation for rhPDGF-BB in treatment of OCD

BioMimetic Therapeutics, Inc. today announced that it has received orphan drug designation from the Food and Drug Administration for its protein therapeutic, recombinant human platelet derived growth factor, to be used in conjunction with autograft and/or commercially available osteochondral allograft for the treatment of osteochondritis dissecans of the knee, elbow or ankle.

12 Aug 2010

Therapeutics News and Research

ARYx secures bridge financing, reports decrease in net loss to $3.6M for second-quarter 2010

EntreMed second quarter 2010 net loss increases to $0.62 per share

Nile Therapeutics second quarter 2010 net loss decreases to $1.5 million

CTI announces EMEA's validation of expanded PIP for pixantrone

Nymox second-quarter net loss increases to $1.75 million

Scientists discover new signaling pathway to reduce tumour growth in glioblastoma multiforme

Common genetic variation in HLA region associated with late-onset sporadic Parkinson's disease: Research

CRF announces additional featured trials to be presented at Transcatheter Cardiovascular Therapeutics 2010

Trubion Pharmaceuticals signs definitive merger agreement with Emergent BioSolutions

Pro-Pharmaceuticals second-quarter net loss applicable to common stock decreases to $2.5 million

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

Epitomics spins-out Apexigen to develop and commercialize humanized rabbit monoclonal antibodies

Guided Therapeutics second-quarter service revenue increases to $0.8 million

Akela reports $0.1M net income for second-quarter 2010 vs. $1.1M net loss for same period in 2009

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Emergent BioSolutions enters agreement to acquire Trubion Pharmaceuticals

Halozyme Therapeutics granted U.S. patent for recombinant human hyaluronidase enzyme platform

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

FDA grants BioMimetic Therapeutics orphan drug designation for rhPDGF-BB in treatment of OCD

Advancing therapeutic biopolymer development eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News